Oyster Point Pharma

CompanyUnited States

Oyster Point Pharma develops one asset, approved (varenicline in smoking). Mostly small molecule acting on CHRNA4, CHRNB2 and CHRNA7; based in the United States.

1
Asset
Furthest: Approved; 7
Trials: 0
Signals

Pipeline

1

varenicline
Partial agonist of alpha-4 beta-2 nicotinic acetylcholine receptors.
Approved, Small molecule, CHRNA4, CHRNB2, smoking, smoking cessation

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials10
Similar companies6

Updated 7 Oct 2026 · 24 sources